These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 33112946

  • 1. Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis.
    Wei CH, Garcia L, Murata-Collins J, Schmolze D, Apple S.
    Arch Pathol Lab Med; 2021 Jul 01; 145(7):887-890. PubMed ID: 33112946
    [Abstract] [Full Text] [Related]

  • 2. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr 01; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 3. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB, Sill DR, Meyer RG, Yuhas JA, Sukov WR, Mounajjed T, Carter JM, Jenkins RB, Chen B.
    Arch Pathol Lab Med; 2021 Jul 01; 145(7):883-886. PubMed ID: 33112955
    [Abstract] [Full Text] [Related]

  • 4. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ.
    JAMA Oncol; 2019 Mar 01; 5(3):366-375. PubMed ID: 30520947
    [Abstract] [Full Text] [Related]

  • 5. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar 01; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 6. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 01; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 7. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0.
    Hoda RS, Brogi E, Xu J, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY.
    Arch Pathol Lab Med; 2020 May 01; 144(5):597-601. PubMed ID: 31647316
    [Abstract] [Full Text] [Related]

  • 8. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B, Ding W, Sun K, Wang X, Xu L, Teng X.
    Sci Rep; 2019 Nov 13; 9(1):16726. PubMed ID: 31723206
    [Abstract] [Full Text] [Related]

  • 9. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
    Gordian-Arroyo AM, Zynger DL, Tozbikian GH.
    Am J Clin Pathol; 2019 Jun 05; 152(1):17-26. PubMed ID: 30958889
    [Abstract] [Full Text] [Related]

  • 10. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH, Wang K, Lin DY, Xu J, Chen J, Long XY, Ge Y, Luo XL, Zhang KP, Liu YH, Xu FP.
    Breast Cancer Res Treat; 2019 May 05; 175(1):51-57. PubMed ID: 30712197
    [Abstract] [Full Text] [Related]

  • 11. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun 05; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 12. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpatt OF, Gomez C, Zhao W, Reis IM.
    Breast Cancer Res Treat; 2016 Feb 05; 155(3):457-62. PubMed ID: 26895325
    [Abstract] [Full Text] [Related]

  • 13. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT.
    Arch Pathol Lab Med; 2009 May 05; 133(5):775-80. PubMed ID: 19415952
    [Abstract] [Full Text] [Related]

  • 14. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, Lim B.
    PLoS One; 2020 May 05; 15(11):e0241775. PubMed ID: 33180796
    [Abstract] [Full Text] [Related]

  • 15. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    J Clin Oncol; 2013 Nov 01; 31(31):3997-4013. PubMed ID: 24101045
    [Abstract] [Full Text] [Related]

  • 16. Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
    Li A, Bai Q, Kong H, Zhou S, Lv H, Zhong S, Li M, Bi R, Zhou X, Yang W.
    Arch Pathol Lab Med; 2020 Sep 01; 144(9):1097-1107. PubMed ID: 32142367
    [Abstract] [Full Text] [Related]

  • 17. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L, Yuan P, Zhang J, Ling Y, Li W, Zhao B, Ying J, Xuan L.
    Breast Cancer Res Treat; 2017 Nov 01; 166(1):77-84. PubMed ID: 28712009
    [Abstract] [Full Text] [Related]

  • 18. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ.
    Histopathology; 2015 Dec 01; 67(6):880-7. PubMed ID: 25913507
    [Abstract] [Full Text] [Related]

  • 19. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology, College of American Pathologists.
    Arch Pathol Lab Med; 2014 Feb 01; 138(2):241-56. PubMed ID: 24099077
    [Abstract] [Full Text] [Related]

  • 20. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR, Shetty S, Wang Z, Rivera CL, Portier BP, Budd GT, Downs-Kelly E, Lanigan CP, Calhoun BC.
    Cancer; 2017 Jun 15; 123(12):2230-2239. PubMed ID: 28192599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.